hotspot
ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
advertisement
Arch declined to comment on the new fundraising.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Diversity in clinical trials starts with building trust, experts say
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
